

Member FINRA/SIPC

Toll-Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432


NRx Pharmaceuticals, Inc. (NRXP) – Buy

January 22, 2024

Announces Completion of Enrollment - P2B/3 NRX-101 in Suicidal Treatment-Resistant Bipolar Depression

Jason H. Kolbert
Managing Director & Senior Analyst
jkolbert@dawsonjames.com

NRx announced the completion of enrollment in its Phase 2b/3 study of NRX-101, the Company's patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. Enrollment of 74 patients exceeded the original target of 70 patients. Positive data from this trial triggers a milestone payment from Alvogen. Alvogen will then be responsible for further development and commercialization costs for this program.



Source: NRx Pharmaceuticals

Stock Data		
52-Week Range	\$0.22	- \$1.32
Shares Outstanding (mil.)	85.2	
Market Capitalization (mil.)	\$36	
Enterprise Value (mil.)	\$27	
Debt to Capital	0%	
Book Value/Share	\$7.69	
Price/Book	10.0	
Average Three Months Trading Volume (K)	120	
Insider Ownership	32.2%	
Institutional Ownership	4.2%	
Short interest (mil.)	3.1%	
Dividend / Yield	\$0.00/0.0%	



Investment Highlights:

A Three-Way Deal: Last June NRx announced a three-way deal: NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen will develop and commercialize NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets. NRXP stands to receive a \$10M upfront payment dependent upon achieving a successful read-out from the ongoing P2b/3 clinical trial. NRx is eligible to receive up to \$330 million in milestone payments tied to development progress and sales targets as well as tiered double-digit escalating to the mid-teens royalty payments contingent upon certain sales thresholds in the U.S. and a fixed royalty payment for markets outside the U.S.

The Trial: The Phase 2b/3 trial enrolled 74 patients with suicidal bipolar depression. This is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of Harvard Massachusetts General Hospital. The primary efficacy endpoint is reduction in depression as measured on the MADRS scale and the secondary endpoint is reduction of suicidal ideation as measured by the Clinical Global Impression Suicidality Scale (CGI-SS). As previously disclosed, treatment compliance and concordance of local raters to central raters scores was in excess of 94%, well above the industry standard that is normally seen in CNS trials.

Top-line results are expected later this quarter.

Valuation: Our model does not yet, reflect the “anti-biotic” side of NRX-101. We project our model out to 2033. We apply a 30% risk cut to our projected revenues in our product model in addition to our 30% risk rate applied in our Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP) models. We do assume additional capital raises. We also assume the company repurchases stock in its outyears, (or we may even see a license deal that brings in non-dilutive capital and reduces our assumed development expenses. The result is equal-weighted and averaged and rounded to the nearest whole number to derive our 12-month projected price target of \$2.0.

Risks to our thesis include: 1. Regulatory Approvals; 2. Clinical Science 3. Intellectual Capital 4. Dilution.

Please find Important Disclosures beginning on Page 5.

Valuation: Our valuation for NRx Pharmaceuticals is based on revenue projections out to 2033 and does not currently reflect the antibiotic side of NRX-101. We know the markets are quite large for depression, PTSD, and related disorders. Success in one area leads to other indications. Our model assumes the company does raise additional capital. We remove the prior assumption that with success, the company can repurchase stock (in the out-years). We have previously assumed a license deal (which occurred in June 2023) and this should bring in non-dilutive capital but we also factor in additional raises near term. As a result, we are returning to our original assumptions, and as such our target valuation falls back to \$2.0 (which was based on a fully diluted share count in 2033). In our model, we assume a rising SG&A and R&D as the company commercializes its products and expands its pipeline, coupled with an improving cost of goods sold (COGS) initially at 20% and at scale falling to just 10%. Our valuation models: Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP), use a 30% discount rate. We select 30% for micro-capitalized growth companies, and this represents our highest risk rate. The result of these three models is then equal-weighted and averaged, and rounded to the nearest whole number to provide a 12-month target price.

Exhibit 1. Free Cash Flow Model

Average	\$	2
Price Target	\$	2
Year		2024

DCF Valuation Using FCF (mln):

units ('000)	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E
EBIT	(39,816)	(48,076)	(27,920)	(28,199)	9,519	131,234	216,946	310,656	480,362	531,066	594,126	688,204
Tax Rate	0%	0%	0%	0%	5%	8%	10%	18%	24%	28%	30%	31%
EBIT(1-t)	(39,816)	(48,076)	(27,920)	(28,199)	9,043	120,735	195,252	254,738	365,075	382,367	415,889	474,861
CapEx												
Depreciation												
Change in NWC												
FCF	(39,816)	(48,076)	(27,920)	(28,199)	9,043	120,735	195,252	254,738	365,075	382,367	415,889	474,861
PV of FCF	(67,289)	(62,499)	(27,920)	(21,692)	5,351	54,955	68,363	68,608	75,635	60,936	50,984	44,779
Discount Rate	30%											
Long Term Growth Rate	1%											
Terminal Cash Flow	1,653,826											
Terminal Value YE2033	155,955											
NPV	473,455											
NPV-Debt	-											
Shares out (thousands)	269,006	2033E										
NPV Per Share	\$	1.76										

Source: Dawson James estimates

Exhibit 2. Discounted EPS Model

Current Year	2024
Year of EPS	2033
Earnings Multiple	15
Discount Factor	30%
Selected Year EPS	\$ 2.16
NPV	\$ 3.06

Source: Dawson James estimates

		Discount Rate and Earnings Multiple Varies, Year is Constant					
		2033 EPS					
Earnings Multiple	3.1	5%	10%	15%	20%	25%	30%
	5		\$6.97	\$4.58	\$3.07	\$2.10	\$1.45
10		\$13.94	\$9.17	\$6.15	\$4.19	\$2.90	\$ 2.04
15		\$20.91	\$13.75	\$9.22	\$6.29	\$4.35	\$ 3.06
20		\$27.87	\$18.34	\$12.29	\$8.38	\$5.80	\$ 4.08
25		\$34.84	\$22.92	\$15.37	\$10.48	\$7.25	\$ 5.10
30		\$41.81	\$27.51	\$18.44	\$12.57	\$8.71	\$ 6.12
35		\$48.78	\$32.09	\$21.51	\$14.67	\$10.16	\$ 7.14
40		\$55.75	\$36.68	\$24.58	\$16.76	\$11.61	\$ 8.16

Exhibit 3. Sum-of-the-Parts Model

NRx Pharmaceuticals	LT Gr	Discount Rate	Yrs. to Mkt Peak	% Success	Peak Sales MM's	Term Val
NRX-101 for BPD	1%	30%	5	80%	\$800	\$2,759
NPV						\$1.77
PTSD / Pain	1%	30%	5	0%	\$800	\$2,759
NPV						\$0.00
NPV						
						80%
MM Shrs OS (2030E)						269
Total						\$1.77

Source: Dawson James estimates

Risks to our thesis include 1. Regulatory Approvals; 2. Clinical Science; 3. Intellectual Capital 4. Dilution

- **Regulatory Approvals.** The company's products require regulatory approvals, and there can be no assurances that the requirements to achieve these approvals can be met. Furthermore, even if a drug product is approved, the regulators may impose limitations on the use or marketing of such product.
- **Clinical Science:** The company will need to demonstrate to its "sophisticated" clients (doctors and other physicians) that the product is effective, reliable, accessible, and marketable.
- **The Competitive Landscape & IP.** The company does have intellectual properties and knows how to protect the utility of its drugs; however, our patent position is highly uncertain.
- **Dilution:** The company is likely to incur losses for the foreseeable future until it is able to generate sufficient revenue from product sales. Our model assumes a rising share count. There can be no assurances that the company can successfully raise the capital required to execute its business strategy.

Exhibit 4. Income Statement


NRx Pharmaceuticals: Income Statement																
000 : YE December 31	2022A	1Q23A	2Q23A	3Q23A	4Q23E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E
Product sales	-	-	-	-	-	-	-	-	50,000	200,000	300,000	400,000	600,000	660,000	726,000	798,600
NRX-101 for BPD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
PTSD / Pain	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Product Sales	-	-	-	-	-	-	-	-	50,000	200,000	300,000	400,000	600,000	660,000	726,000	798,600
Expenses																
COGS									12,000	40,000	54,000	60,000	90,000	99,000	101,640	79,860
COGS %	0%	0%	0%	0%	0%	0%	0%	0%	24%	20%	18%	15%	15%	15%	14%	10%
Research and Development	17,027	3,650	3,873	3,314	4,000	14,837	17,804	21,365	17,092	13,674	13,811	15,192	18,230	21,876	22,095	22,316
General and Administrative	27,370	5,785	4,065	2,494	3,000	15,344	15,497	15,652	15,809	15,967	16,127	16,288	16,451	16,615	16,782	16,949
Settlement Expense	-	-	250	-	-	-	-	-	-	-	-	-	-	-	-	-
Reimbursement of expenses from Relief Therapeutics	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	44,397	9,435	8,188	5,808	7,000	30,181	15,497	15,652	27,809	55,967	70,127	76,288	106,451	115,615	118,422	96,809
Loss from Operations	(44,397)	(9,435)	(8,188)	(5,808)	(7,000)	(30,181)	(15,497)	(15,652)	22,191	144,033	229,873	323,712	493,549	544,385	607,578	701,791
Other (income) Expenses																
Gain on extinguishment of debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income	(249)	(156)	(145)	(119)	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense - Convertible note	505	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability	(255)	1,772	663	373	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of Earnout Cash liability	(4,582)	(12)	11	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other (income) expense	(4,581)															
Net Loss	(39,816)	(11,039)	(8,717)	(6,062)	(7,000)	(30,181)	(15,497)	(15,652)	22,191	144,033	229,873	323,712	493,549	544,385	607,578	701,791
	-	(106)	128	-	-	22	-	-	1,110	11,523	22,987	58,268	118,452	152,428	182,274	217,555
Tax Rate	0%	0%	0%	0%	0%	0%	0%	0%	5%	8%	10%	18%	24%	28%	30%	31%
GAAP Net Income (loss)	(39,816)	(10,933)	(8,845)	(6,062)	(7,000)	(30,203)	(15,497)	(15,652)	21,082	132,510	206,886	265,444	375,097	391,957	425,305	484,236
GAAP-EPS	(0.61)	(0.16)	(0.12)	(0.07)	(0.05)	(0.41)	(0.10)	(0.08)	0.10	0.62	0.96	1.23	1.73	1.80	1.94	2.20
GAAP EPS (dil)	(0.61)	(0.13)	(0.09)	(0.06)	(0.05)	(0.28)	(0.09)	(0.07)	0.08	0.50	0.78	1.00	1.41	1.80	1.94	2.20
Wgtd Avg Shrs (Bas) '000	65,767	67,454	73,221	81,947	130,406	88,257	150,062	194,208	213,881	214,738	215,598	216,462	217,329	218,200	219,074	219,622
Wgtd Avg Shrs (Dil) '000	65,767	82,897	103,726	100,000	151,000	109,406	176,213	234,085	261,963	263,012	264,066	265,124	266,186	267,252	268,323	268,994

Source: Dawson James estimates, company reports

Companies mentioned in this report:

Important Disclosures:

Price Chart:



Price target and ratings changes over the past three years:

- Initiated – Buy – March 17, 2023 – Price Target \$3.0
- Update Report – March 27, 2023 – Price Target \$3.0
- Update Report – March 31, 2023 – Price Target \$3.0
- Price Target Change- April 3, 2023 Price Target goes from \$3.0 to \$9.0
- Update Report – April 5, 2023 – Price Target \$9.0
- Update Report – May 17, 2023 – Price Target \$9.0
- Update Report – June 5, 2023 – Price Target \$9.0
- Update Report – August 7, 2023 – Price Target \$9.0
- Update Report – August 15, 2023 – Price Target \$9.0
- Price Target Change – September 7, 2023 – Price Target goes from \$9.0 to \$2.0
- Update Report – October 2, 2023 – Price Target \$2.0
- Update Report – October 16, 2023 – Price Target \$2.0
- Update Report – October 26, 2023 – Price Target \$2.0
- Update Report – November 1, 2023 – Price Target \$2.0
- Update Report – November 6, 2023 – Price Target \$2.0
- Update Report – December 19, 2023 – Price Target \$2.0
- Update Report – January 16, 2024 – Price Target \$2.0
- Update Report – January 22, 2024 – Price Target \$2.0

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has not received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director, or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of January 18, 2024, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts, or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "Valuation" and "Risk Analysis" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Ratings Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months.
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months.
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 18-Jan-24

	Company Coverage		Investment Banking	
Ratings Distribution	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	21	61.76%	4	11.80%
Market Perform (Neutral)	13	38.24%	2	5.90%
Market Underperform (Sell)	0	0%	0	0.00%
Total	34	100%	6	17.70%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.